Contents

Search


centrally-acting ACE inhibitor

Indications: - may slow cognitive decline in patients with dementia - effect is small & of unknown clinical significance - hypertension - diabetic nephropathy - nondiabetic proteinuric nephropathy - chronic heart failure - left ventricular systolic dysfunction - myocardial infarction - left ventricular diastolic dysfunction - scleroderma, scleroderma renal crisis - migraine prophylaxis - ischemic stroke - cystinuria, cysteine renal calculi

Interactions

drug adverse effects of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors) monitor with ACE inhibitors

Specific

captopril (Capoten) fosinopril (Monopril) lisinopril (Prinivil, Zestril) perindopril (Aceon, Coversyl) ramipril (Altace) trandolapril (Mavik, indolapril)

General

angiotensin-converting enzyme (ACE) inhibitor

References

  1. Gao Y, O'Caoimh R, Healy L et al Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013;3:e002881 PMID: 23887090 http://bmjopen.bmj.com/content/3/7/e002881
  2. Deprecated Reference